A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
about
Pancreatic cancer: New hopes after first line treatmentFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerAnalytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNANeoadjuvant treatment for resectable pancreatic adenocarcinoma.The potential for liquid biopsies in the precision medical treatment of breast cancer.SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.Selumetinib in the treatment of non-small-cell lung cancer.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.Role of microenvironmental periostin in pancreatic cancer progression.A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer.Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.Targeted Therapies for Pancreatic Cancer.MEK inhibitors for the treatment of NRAS mutant melanomaImmune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future OptionsCurrent status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?Naturally occurring compounds as pancreatic cancer therapeutics
P2860
Q28067055-E3179341-45F6-4EE1-B830-9BA95753EBA4Q28075540-5CA907EE-60BC-445A-83F3-FEAF29BA94F3Q35810461-A6D3A7A3-01F8-459C-9330-63EC8523F67CQ36526141-9BF496E8-2933-4E93-83C7-582AFD424DDCQ36849660-02B1AC79-F679-4A1C-AB29-7D03EBADCB09Q38702971-5E2C1490-A673-44BF-97C3-635A6391F06BQ38836927-4927B2B2-34E7-4BB7-BF9E-AE3CB1A439ACQ39204274-B69231B8-0554-414C-A40F-D085C9E7F1F0Q42363767-297854E4-3F11-4D8E-9B57-34151E00502CQ42678871-04B36104-F040-42EE-B076-946EFE439D71Q45771543-73E65AD0-3971-40EF-8E24-CD81F3A512F0Q47122011-378D00ED-CD07-4B56-B8CE-AC33F068C98AQ51638544-C6CE8DF6-47B6-4F01-8AAA-7B2FCD3D7243Q54277914-07B6C8AC-3F46-4B39-BBEB-75D50E53A65DQ54974100-0444639E-19DA-4A2B-9531-E5E44960C773Q55015991-F4B1A7B0-DC56-4ABF-B032-B6CC990BE88EQ56889985-7190C637-A3B8-44A9-8921-1D9871A10B10Q56890107-97C2F07F-F374-4207-AAE5-F5E09CBE829BQ58799265-BB6AC3C8-0969-43AC-9F0B-AB277F167747Q59128443-ACD7FDB9-DDDC-411A-B483-954CFE121849
P2860
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A Multicenter, Open-Label Phas ...... ced Pancreatic Adenocarcinoma.
@ast
A Multicenter, Open-Label Phas ...... ced Pancreatic Adenocarcinoma.
@en
type
label
A Multicenter, Open-Label Phas ...... ced Pancreatic Adenocarcinoma.
@ast
A Multicenter, Open-Label Phas ...... ced Pancreatic Adenocarcinoma.
@en
prefLabel
A Multicenter, Open-Label Phas ...... ced Pancreatic Adenocarcinoma.
@ast
A Multicenter, Open-Label Phas ...... ced Pancreatic Adenocarcinoma.
@en
P2093
P2860
P921
P1476
A Multicenter, Open-Label Phas ...... ced Pancreatic Adenocarcinoma.
@en
P2093
Alan P Venook
AmirAli Talasaz
Andrew H Ko
Elizabeth Dito
Eric A Collisson
Jessica Van Ziffle
Margaret A Tempero
Nancy M Joseph
Olga M Mirzoeva
P2860
P356
10.1158/1078-0432.CCR-15-0979
P407
P577
2015-08-06T00:00:00Z